Despite recent advances in therapy, multiple myeloma (MM) remains incurable, showing the need for novel therapies.
Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. Melflufen is currently being evaluated for the treatment of multiple myeloma in a phase III study.